CINXE.COM

The future of cell therapy development and delivery - Endpoints Webinars

<!DOCTYPE html> <html lang="en"> <head> <title>The future of cell therapy development and delivery - Endpoints Webinars</title> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta http-equiv="content-type" content="text/html; charset=utf-8"> <meta name="viewport" content="width=device-width, user-scalable=no"> <link rel="apple-touch-icon" sizes="180x180" href="/assets/images/favicon/apple-touch-icon.png"> <link rel="icon" type="image/png" sizes="32x32" href="/assets/images/favicon/favicon-32x32.png"> <link rel="icon" type="image/png" sizes="16x16" href="/assets/images/favicon/favicon-16x16.png"> <link rel="manifest" href="/assets/images/favicon/site.webmanifest"> <link rel="mask-icon" href="/assets/images/favicon/safari-pinned-tab.svg" color="#5bbad5"> <link rel="shortcut icon" href="/assets/images/favicon/favicon.ico"> <meta name="msapplication-TileColor" content="#da532c"> <meta name="msapplication-config" content="/assets/images/favicon/browserconfig.xml"> <meta name="theme-color" content="#ffffff"> <meta property="og:description" content="Key Takeaways: - Explore the latest strategies for navigating the complexities of cell therapy development - Identify clinical development best practices for a successful execution - Learn insights into the cutting-edge advancements that are driving the future of cell therapy" /> <meta property="og:title" content="The future of cell therapy development and delivery - Endpoints Webinars" /> <meta property="og:url" content="https://webinars.endpts.com/the-future-of-cell-therapy-development-and-delivery/" /> <meta property="og:site_name" content="Endpoints Webinars" /> <meta property="og:type" content="article" /> <meta property="article:section" content="Business & Health" /> <meta name="twitter:site" content="@endpts"> <link rel="canonical" href="https://webinars.endpts.com/the-future-of-cell-therapy-development-and-delivery/" /> <meta property="og:image" content="https://webinars.endpts.com/assets/images/the-future-of-cell-therapy-development-and-delivery/social_preview.jpg" /> <meta property="twitter:image" content="https://webinars.endpts.com/assets/images/the-future-of-cell-therapy-development-and-delivery/social_preview.jpg" /> <meta name="twitter:card" content="summary_large_image"><link href="https://webinars.endpts.com/assets/css/bootstrap.min.css" rel="stylesheet" type="text/css"> <link href="https://webinars.endpts.com/assets/css/style.css?v=1.0.17" rel="stylesheet" type="text/css"> <link href="https://webinars.endpts.com/assets/css/the-future-of-cell-therapy-development-and-delivery.css?v=1.0.17" rel="stylesheet" type="text/css"> <script async src="https://www.googletagmanager.com/gtag/js?id=G-ZS375P62LY"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-ZS375P62LY'); gtag('config', 'AW-370093343'); </script> </head> <body id="page-the-future-of-cell-therapy-development-and-delivery"> <header class="header_area"> <div class="main_menu"> <nav class="navbar navbar-expand-lg navbar-light"> <div class="container navi-border"> <a href="/" title="Endpoints Webinars"> <div class="navbar-brand logo_h"> <svg version="1.1" width="280px" class="d-inline-block align-top ew-logo" alt="Endpoints Webinars" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewbox="0 0 280 46" style="enable-background:new 0 0 280 46;" xml:space="preserve"> <path class="ew-logo-primary" d="M84.3,0.2l-7.7,24.1h-0.5l-8-24.1h-7.8l-7.3,24.1h-0.5L44.3,0.2h-4h-8.8H0V46h39l-3.9-10.2h-24v-8.1h20.6 L28.1,18h-17v-7.6h24.3L48.7,46h7.7l8-25.6h0.4L72.2,46h7.7L97.1,0.2H84.3z"></path> <path class="ew-logo-secondary" d="M122.2,33.3l-4.5,12.5h-1l-7-17.7l2.5-0.5l4.9,12.8h0.2l4.5-12.8h0.6l4.7,12.8h0.2l4.8-12.8l2.5,0.5l-7,17.7h-1 L122.2,33.3C122.4,33.3,122.2,33.3,122.2,33.3z M151.2,30.1H142v5.3h8.1v2.3H142v5.7h9.5v2.3h-12.1V27.8h11.7L151.2,30.1L151.2,30.1 z M166.8,36.5c2.2,0.4,3.7,2.1,3.7,4.2c0,3.1-2.4,4.9-6.3,4.9h-6.4V27.8h5.9c4.2,0,5.8,2.4,5.8,4.7c0,1.6-0.8,3.1-2.6,3.8V36.5 L166.8,36.5z M163.7,30.1h-3.5v5.3h3.6c1.9,0,2.9-0.9,2.9-2.7C166.7,30.7,165.3,30.1,163.7,30.1z M160.2,37.7v5.7h4.2 c1.9,0,3.4-0.9,3.4-2.8s-1.6-2.9-3.6-2.9L160.2,37.7L160.2,37.7z M179.1,45.6h-2.5V27.8h2.5V45.6z M199.9,40.7l0.3-0.1V27.8h2.5 v17.8l-1,0.3l-12.3-13l-0.3,0.1v12.7h-2.5V27.9l1-0.3L199.9,40.7z M220.1,41.5h-8.2l-1.9,4.3l-2.6-0.4l8.3-17.8h0.5l8.4,17.8 l-2.6,0.4L220.1,41.5z M212.9,39.2h6.1l-3-6.6h-0.1L212.9,39.2z M243.5,45v0.4l-2.4,0.5l-6.3-7.2h-2.9v7h-2.5V27.8h6.5 c3.7,0,6.1,2.2,6.1,5.3c0,2.7-1.6,4.7-4.4,5.2L243.5,45z M235.8,30.1h-3.8v6.3h3.8c2.3,0,3.7-1.1,3.7-3.3 C239.5,31.1,237.9,30.1,235.8,30.1z M248.5,41.7c1.5,1.2,3.2,1.9,5.6,1.9c3.1,0,4.2-1.3,4.2-2.7c0-1.6-1.5-2.3-4.5-3.6 c-4.1-1.8-5.5-2.9-5.5-5.2s2.1-4.7,6.1-4.7c2.7,0,4.9,0.9,6,1.9l-0.9,2.1c-1.5-1.1-3.2-1.6-5.1-1.6c-2.3,0-3.7,1-3.7,2.2 c0,1.3,1.1,1.9,4.7,3.4c4.1,1.6,5.4,3.3,5.4,5.7c0,3-2.6,4.9-6.9,4.9c-2.9,0-5.5-1.1-6.5-2.1L248.5,41.7z M122.8,4.6h-8.1v3h7.1v3.8 h-7.1v3.2h8.4v4H110V0.6h12.8L122.8,4.6L122.8,4.6z M141.2,10.9h0.2V0.6h4.7v18.1h-3l-9.7-10.3h-0.2v10.3h-4.7V0.6h3L141.2,10.9z M151.7,18.7V0.6h6.4c5.4,0,9.5,3.7,9.5,9.1c0,5.8-4,9.1-9.5,9.1C158.1,18.7,151.7,18.7,151.7,18.7z M158.4,14.7 c2.6,0,4.4-1.8,4.4-5.1c0-3.1-2.5-4.9-4.5-4.9h-2.1v10.1C156.2,14.7,158.4,14.7,158.4,14.7z M178.9,12.5H177v6.2h-4.7V0.6h6.7 c4.1,0,7,2.4,7,6.3C186,9.3,184.3,12.5,178.9,12.5z M178.5,4.4H177v4.5h1.6c1.5,0,2.5-0.7,2.5-2.1C181.1,5.5,180,4.4,178.5,4.4z M199.3,19.1c-5.7,0-9.7-4.1-9.7-9.3c0-5.8,4.7-9.5,9.7-9.5c4.9,0,9.7,3.7,9.7,9.5C208.9,14.9,205.1,19.1,199.3,19.1z M199.2,4.4 c-2.5,0-4.9,1.9-4.9,5.3c0,2.7,1.6,5.3,4.9,5.3c2.7,0,4.9-2,4.9-5.3C204.1,6.5,201.9,4.4,199.2,4.4z M218.6,18.7h-4.7V0.6h4.7V18.7z M237.3,10.9h0.2V0.6h4.7v18.1h-3l-9.7-10.3h-0.2v10.3h-4.7V0.6h3L237.3,10.9z M257,4.6v14.1h-4.7V4.6h-5.5v-4h15.6v4H257L257,4.6z M267.1,13.2c1.6,1,3.7,1.9,5.8,1.9c1.6,0,2.4-0.7,2.4-1.5c0-1.1-1.2-1.5-3.5-2.6c-3.7-1.7-5.2-3-5.2-5.7s2.2-5.2,6.7-5.2 c2.6,0,4.8,0.6,6.4,1.7l-1.2,3.8c-1.8-1-3.6-1.6-5.3-1.6c-1.4,0-2,0.5-2,1.3s0.7,1.2,3.6,2.5c3.9,1.8,5.3,3.5,5.3,5.9 c0,3.4-3.1,5.2-7.4,5.2c-3.1,0-5.8-1.1-6.9-2.1L267.1,13.2z"></path> </svg> </div> </a> <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarSupportedContent" aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation"> <span class="icon-bar"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> </button> <div class="collapse navbar-collapse offset" id="navbarSupportedContent"> <ul class="nav navbar-nav menu_nav justify-content-end"> <li class="nav-item"> <a class="nav-link" href="https://endpts.com" target="_blank" title="Endpoints News">Endpoints News</a> </li> <li class="reg-button" data-block-name="register">watch now</li> </ul> </div> </div> </nav> </div> </header> <section id="hero-section"> <div class="container"> <div class="row d-flex no-gutters date-time"> <div class="on-demand">WEBINAR RECORDING AVAILABLE - WATCH ON DEMAND</div> </div> <div class="hero-content"> <h1>The future of cell therapy development and delivery</h1> <div class="abstract"> <h5>Key Takeaways:</h5> <ul> <li>Explore the latest strategies for navigating the complexities of cell therapy development</li> <li>Identify clinical development best practices for a successful execution</li> <li>Learn insights into the cutting-edge advancements that are driving the future of cell therapy</li> </ul> </div> <!-- abstract --> <div class="col-md-12 align-self-center sponsor-part">SPONSORED BY <a href="https://www.precisionmedicinegrp.com/advance/" target="_blank" rel="noopener nofollow"><img src="/assets/images/the-future-of-cell-therapy-development-and-delivery/sponsor-logo.png"></a> </div> </div> </div> <div class="fixed-bottom cta-fixed"> <div class="container"> <div class="row d-flex"> <div class="col-md-3 align-self-center social order-3 order-md-1">SHARE ON <a href="https://www.linkedin.com/shareArticle?mini=true&source=https%3A%2F%2Fwebinars.endpts.com%2F&title=Endpoints+Webinars%3A+The+future+of+cell+therapy+development+and+delivery&url=https%3A%2F%2Fwebinars.endpts.com%2Fthe-future-of-cell-therapy-development-and-delivery" target="_blank" rel="noopener nofollow"><img src="/assets/images/social/social-linkedin.svg"></a> <a href="https://twitter.com/intent/tweet?text=Endpoints+Webinars%3A+The+future+of+cell+therapy+development+and+delivery+https%3A%2F%2Fwebinars.endpts.com%2Fthe-future-of-cell-therapy-development-and-delivery" target="_blank" rel="noopener nofollow"><img src="/assets/images/social/social-twitter.svg"></a> </div> <div class="col-md-5 order-1"> </div> <div class="col-md-4 align-self-center order-2"> <div class="reg-button" data-block-name="register">watch now</div> </div> </div> </div> </div> </section><section class="pt-5 register-section" id="register"> <div class="container register-states pt-4"> <div class="section-title mb-0">Watch the webinar on demand</div> <div class="col-md-4 m-auto"> <a class="reg-button" href="https://vimeo.com/855465930/e495f4bfdc" target="_blank" rel="noopener nofollow">watch now</a> </div> </div> </section> <section class="speakers-section"> <div class="container"> <div class="row speaker-row align-items-top"> <div class="col-lg-3 col-sm-4 mb-lg-0 mb-4"> <img class="card-img rounded-circle" src="/assets/images/the-future-of-cell-therapy-development-and-delivery/panelists/ChrisMcDonald.jpg" alt="Chris McDonald" /> </div><!-- speaker-photo --> <div class="col-lg-9 col-sm-8 speaker-info"> <h3>Chris McDonald</h3> <h5>Global Head of Technical Operations, Kite Therapeutics</h5> <p>Chris leads the Global Technical Operations department (Tech Ops), which includes Global Manufacturing, Global Quality, Process Development, and the Global Supply Chain. </p> <p>Prior to leading Tech Ops, Chris led the Global Manufacturing Leadership Team (GMLT), which includes the Site Operational Leaders and cross-functional partners from Quality, MSAT, IT, HR and Finance. Chris was responsible for viral vector, clinical and commercial cell therapy operations, developing manufacturing strategy, executing site operations, ensuring cGMP compliance, establishing new manufacturing facilities, building teams and developing people. Additionally, Chris was responsible for culture development at our sites driving an inclusive culture of safety, quality and production excellence.</p> <p>Chris is a global business leader with over 30 years of biotech and pharmaceutical operations experience across various functions within Technical Operations. Chris joined Kite in 2018 as Site Head of Cell Therapy Operations in Fredrick, MD. Prior to that Chris was with Astra Zeneca, where he was VP & Site Head of Operations for their monoclonal antibody site. Previously Chris spent 10 years at Novartis in positions of increased responsibility, including VP & Site Head of Vaccines Operations, and VP & Global Head of Technical Operations Strategy. In this role Chris was responsible for product life cycle management, long range production planning and manufacturing network strategy for a network operating in eight countries. Prior to his time at Novartis, Chris held various manufacturing and engineering leadership roles at Amgen.</p> <p>Chris holds a bachelor’s degree in Computer Science from Eastern Michigan University and master’s degree in business from the Fuqua School of Business at Duke University.</p> </div><!-- speaker-info --> </div><!-- speaker-row --> <div class="row speaker-row align-items-top"> <div class="col-lg-3 col-sm-4 mb-lg-0 mb-4"> <img class="card-img rounded-circle" src="/assets/images/the-future-of-cell-therapy-development-and-delivery/panelists/JasonFoster.jpg" alt="Jason Foster" /> </div><!-- speaker-photo --> <div class="col-lg-9 col-sm-8 speaker-info"> <h3>Jason Foster</h3> <h5>CEO, Ori Biotech</h5> <p>Jason is CEO of Ori Biotech, based in London and New Jersey. Ori has developed a fully automated and standardised cell and gene therapy manufacturing platform. And over the past 20 years, Jason has held leading roles building: pharma, consulting and technology companies.</p> </div><!-- speaker-info --> </div><!-- speaker-row --> <div class="row speaker-row align-items-top"> <div class="col-lg-3 col-sm-4 mb-lg-0 mb-4"> <img class="card-img rounded-circle" src="/assets/images/the-future-of-cell-therapy-development-and-delivery/panelists/MarkFrattini.jpg" alt="Mark Frattini" /> </div><!-- speaker-photo --> <div class="col-lg-9 col-sm-8 speaker-info"> <h3>Mark Frattini</h3> <h5>CMO, Cellectis</h5> <p>In September 2022, Mark Frattini, M.D., Ph.D., was appointed Cellectis' Chief Medical Officer.</p> <p>Dr. Frattini has over 20 years of experience in the field of hematological malignancies and joined Cellectis in August 2020 as Senior Vice President of Clinical Sciences where he has been responsible for Cellectis’ clinical leadership including the clinical development strategy of the Company’s current immune-oncology UCART product candidates. He has also been serving as a core member of the senior clinical team. As Chief Medical Officer, Dr. Frattini oversees clinical research and development for Cellectis’ UCART clinical trial programs.</p> <p>Prior to joining Cellectis, Dr. Frattini was Executive Medical Director, Program Lead, Global Clinical Research & Development at Celgene/Bristol Myer Squibb and was responsible for the oversight and management of several of Celgene’s sponsored programs in the hematology therapeutic area. Before joining Celgene, Dr. Frattini spent over 16 years as a physician-scientist specializing in hematologic malignancies in academia at Memorial Sloan-Kettering Cancer Center and Columbia University where he was a member of the adult leukemia service and the Experimental Therapeutics center at both institutions. At Columbia University from 2013-2018 Mark also served as the Director of Research for Hematologic Malignancies.</p> <p>Dr. Frattini holds a M.D. and Ph.D. in Biochemistry and Molecular Biology from The University of Chicago and received his Internal Medicine residency and Medical Oncology fellowship training at Johns Hopkins Hospital.</p> </div><!-- speaker-info --> </div><!-- speaker-row --> <div class="row speaker-row align-items-top"> <div class="col-lg-3 col-sm-4 mb-lg-0 mb-4"> <img class="card-img rounded-circle" src="/assets/images/the-future-of-cell-therapy-development-and-delivery/panelists/PhilCyr.jpg" alt="Phil Cyr" /> </div><!-- speaker-photo --> <div class="col-lg-9 col-sm-8 speaker-info"> <h3>Phil Cyr</h3> <h5>SVP, Precision Value & Health</h5> <p>Phil Cyr, MPH, is Senior Vice President of Customer Solutions for Precision Value & Health with responsibility for cell and gene therapy. Phil has over 26 years of health economics, outcomes research, health policy, and payer experience, including a strong record of conducting published research, conducting health technology appraisal within a U.S. payer, and interacting with global HTAs. Phil and his team have built the health economic evidence and value demonstration strategy for over 15 gene therapies.</p> </div><!-- speaker-info --> </div><!-- speaker-row --> <div class="row speaker-row align-items-top"> <div class="col-lg-3 col-sm-4 mb-lg-0 mb-4"> <img class="card-img rounded-circle" src="/assets/images/the-future-of-cell-therapy-development-and-delivery/panelists/AndyKinley.jpg" alt="Andy Kinley" /> </div><!-- speaker-photo --> <div class="col-lg-9 col-sm-8 speaker-info"> <h3>Andy Kinley</h3> <h5>VP, Innovation and Clinical Science, Precision for Medicine</h5> <p>Andy Kinley, Ph.D., is Vice President of Innovation and Clinical Science at Precision for Medicine. He is a clinical researcher with over 25 years of combined experience leading basic and clinical research in oncology and hematology. His early scientific career focused on cancer cell signaling, setting a foundation to complement his clinical research roles in trial design and implementation of effective strategies for oncology clinical trials. Andy specializes in immuno-oncology trials (checkpoint inhibitors, T-cell agonists, bispecifics, cytokines, oncolytic viruses, neoantigen cancer vaccines), including autologous and allogeneic adoptive cell therapies (CAR-T, TCR, TIL, NK cells). Today, Andy identifies and implements innovative tools, datasets, and services that can impact clinical trial execution including quality, patient diversity, site identification, and trial timelines.</p> </div><!-- speaker-info --> </div><!-- speaker-row --> <div class="row speaker-row align-items-top"> <div class="col-lg-3 col-sm-4 mb-lg-0 mb-4"> <img class="card-img rounded-circle" src="/assets/images/the-future-of-cell-therapy-development-and-delivery/panelists/JohnKhoury.jpg" alt="John Khoury"> </div> <!-- speaker-photo --> <div class="col-lg-9 col-sm-8 speaker-info"> <h6>moderator</h6> <h3>John Khoury</h3> <h5>EVP, Project Farma</h5> <p>John Khoury is a 20+ year veteran and leader in the biotech / pharmaceutical industry. As a member of the Project Farma Leadership Committee, John has spearheaded Project Farma’s growth in the gene and cell therapy space. He has led and provided strategy on key partner initiatives including make vs. buy analysis, site and vendor selection, tech transfer execution strategies, and facility start-ups.</p> <p>In addition to his experience in advanced therapies, John has extensive experience with small and large molecules including biologics and biosimilars. Over the past four years, he has led facility builds totaling over $500MM. During this time, he has worked with small and large biotech and pharmaceutical companies including gene and cell therapy startups and CMOs/CROs.</p> </div> <!-- speaker-info --> </div><!-- speaker-row --> </div> </section> <div class="modal" role="dialog" id="registration_success" aria-hidden="true"> <div class="modal-dialog modal-dialog-centered" role="document"> <div class="modal-content"> <div class="modal-header align-items-center"> <svg version="1.1" width="280px" class="d-inline-block align-top ew-logo" alt="Endpoints Webinars" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewbox="0 0 280 46" style="enable-background:new 0 0 280 46;" xml:space="preserve"> <path class="ew-logo-primary" d="M84.3,0.2l-7.7,24.1h-0.5l-8-24.1h-7.8l-7.3,24.1h-0.5L44.3,0.2h-4h-8.8H0V46h39l-3.9-10.2h-24v-8.1h20.6 L28.1,18h-17v-7.6h24.3L48.7,46h7.7l8-25.6h0.4L72.2,46h7.7L97.1,0.2H84.3z"/> <path class="ew-logo-secondary" d="M122.2,33.3l-4.5,12.5h-1l-7-17.7l2.5-0.5l4.9,12.8h0.2l4.5-12.8h0.6l4.7,12.8h0.2l4.8-12.8l2.5,0.5l-7,17.7h-1 L122.2,33.3C122.4,33.3,122.2,33.3,122.2,33.3z M151.2,30.1H142v5.3h8.1v2.3H142v5.7h9.5v2.3h-12.1V27.8h11.7L151.2,30.1L151.2,30.1 z M166.8,36.5c2.2,0.4,3.7,2.1,3.7,4.2c0,3.1-2.4,4.9-6.3,4.9h-6.4V27.8h5.9c4.2,0,5.8,2.4,5.8,4.7c0,1.6-0.8,3.1-2.6,3.8V36.5 L166.8,36.5z M163.7,30.1h-3.5v5.3h3.6c1.9,0,2.9-0.9,2.9-2.7C166.7,30.7,165.3,30.1,163.7,30.1z M160.2,37.7v5.7h4.2 c1.9,0,3.4-0.9,3.4-2.8s-1.6-2.9-3.6-2.9L160.2,37.7L160.2,37.7z M179.1,45.6h-2.5V27.8h2.5V45.6z M199.9,40.7l0.3-0.1V27.8h2.5 v17.8l-1,0.3l-12.3-13l-0.3,0.1v12.7h-2.5V27.9l1-0.3L199.9,40.7z M220.1,41.5h-8.2l-1.9,4.3l-2.6-0.4l8.3-17.8h0.5l8.4,17.8 l-2.6,0.4L220.1,41.5z M212.9,39.2h6.1l-3-6.6h-0.1L212.9,39.2z M243.5,45v0.4l-2.4,0.5l-6.3-7.2h-2.9v7h-2.5V27.8h6.5 c3.7,0,6.1,2.2,6.1,5.3c0,2.7-1.6,4.7-4.4,5.2L243.5,45z M235.8,30.1h-3.8v6.3h3.8c2.3,0,3.7-1.1,3.7-3.3 C239.5,31.1,237.9,30.1,235.8,30.1z M248.5,41.7c1.5,1.2,3.2,1.9,5.6,1.9c3.1,0,4.2-1.3,4.2-2.7c0-1.6-1.5-2.3-4.5-3.6 c-4.1-1.8-5.5-2.9-5.5-5.2s2.1-4.7,6.1-4.7c2.7,0,4.9,0.9,6,1.9l-0.9,2.1c-1.5-1.1-3.2-1.6-5.1-1.6c-2.3,0-3.7,1-3.7,2.2 c0,1.3,1.1,1.9,4.7,3.4c4.1,1.6,5.4,3.3,5.4,5.7c0,3-2.6,4.9-6.9,4.9c-2.9,0-5.5-1.1-6.5-2.1L248.5,41.7z M122.8,4.6h-8.1v3h7.1v3.8 h-7.1v3.2h8.4v4H110V0.6h12.8L122.8,4.6L122.8,4.6z M141.2,10.9h0.2V0.6h4.7v18.1h-3l-9.7-10.3h-0.2v10.3h-4.7V0.6h3L141.2,10.9z M151.7,18.7V0.6h6.4c5.4,0,9.5,3.7,9.5,9.1c0,5.8-4,9.1-9.5,9.1C158.1,18.7,151.7,18.7,151.7,18.7z M158.4,14.7 c2.6,0,4.4-1.8,4.4-5.1c0-3.1-2.5-4.9-4.5-4.9h-2.1v10.1C156.2,14.7,158.4,14.7,158.4,14.7z M178.9,12.5H177v6.2h-4.7V0.6h6.7 c4.1,0,7,2.4,7,6.3C186,9.3,184.3,12.5,178.9,12.5z M178.5,4.4H177v4.5h1.6c1.5,0,2.5-0.7,2.5-2.1C181.1,5.5,180,4.4,178.5,4.4z M199.3,19.1c-5.7,0-9.7-4.1-9.7-9.3c0-5.8,4.7-9.5,9.7-9.5c4.9,0,9.7,3.7,9.7,9.5C208.9,14.9,205.1,19.1,199.3,19.1z M199.2,4.4 c-2.5,0-4.9,1.9-4.9,5.3c0,2.7,1.6,5.3,4.9,5.3c2.7,0,4.9-2,4.9-5.3C204.1,6.5,201.9,4.4,199.2,4.4z M218.6,18.7h-4.7V0.6h4.7V18.7z M237.3,10.9h0.2V0.6h4.7v18.1h-3l-9.7-10.3h-0.2v10.3h-4.7V0.6h3L237.3,10.9z M257,4.6v14.1h-4.7V4.6h-5.5v-4h15.6v4H257L257,4.6z M267.1,13.2c1.6,1,3.7,1.9,5.8,1.9c1.6,0,2.4-0.7,2.4-1.5c0-1.1-1.2-1.5-3.5-2.6c-3.7-1.7-5.2-3-5.2-5.7s2.2-5.2,6.7-5.2 c2.6,0,4.8,0.6,6.4,1.7l-1.2,3.8c-1.8-1-3.6-1.6-5.3-1.6c-1.4,0-2,0.5-2,1.3s0.7,1.2,3.6,2.5c3.9,1.8,5.3,3.5,5.3,5.9 c0,3.4-3.1,5.2-7.4,5.2c-3.1,0-5.8-1.1-6.9-2.1L267.1,13.2z"/> </svg> <button class="ui_form_close" data-dismiss="modal">close</button> </div> <div class="modal-body"> <div class="row"> <div class="col-12 modal-container"> <h1>Your seat is reserved!</h1> <h2>The future of cell therapy development and delivery</h2> <div class="time"> 12:00 pm - 1:00 pm EDT </div> <div class="time local-time">LOCAL TIME</div> <p>A confirmation email with information on how to join the webinar has been sent to you.</p> <p>Before joining, be sure to check <a href="https://support.zoom.us/hc/en-us/articles/201362023-System-requirements-for-Windows-macOS-and-Linux" target="_blank" rel="noopener nofollow">system requirements</a> to avoid any connection issues. </p> </div> </div> </div> </div> </div> </div> <div class="modal" role="dialog" id="registration_declined" aria-hidden="true"> <div class="modal-dialog modal-dialog-centered" role="document"> <div class="modal-content"> <div class="modal-header align-items-center"> <svg version="1.1" width="280px" class="d-inline-block align-top ew-logo" alt="Endpoints Webinars" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewbox="0 0 280 46" style="enable-background:new 0 0 280 46;" xml:space="preserve"> <path class="ew-logo-primary" d="M84.3,0.2l-7.7,24.1h-0.5l-8-24.1h-7.8l-7.3,24.1h-0.5L44.3,0.2h-4h-8.8H0V46h39l-3.9-10.2h-24v-8.1h20.6 L28.1,18h-17v-7.6h24.3L48.7,46h7.7l8-25.6h0.4L72.2,46h7.7L97.1,0.2H84.3z"/> <path class="ew-logo-secondary" d="M122.2,33.3l-4.5,12.5h-1l-7-17.7l2.5-0.5l4.9,12.8h0.2l4.5-12.8h0.6l4.7,12.8h0.2l4.8-12.8l2.5,0.5l-7,17.7h-1 L122.2,33.3C122.4,33.3,122.2,33.3,122.2,33.3z M151.2,30.1H142v5.3h8.1v2.3H142v5.7h9.5v2.3h-12.1V27.8h11.7L151.2,30.1L151.2,30.1 z M166.8,36.5c2.2,0.4,3.7,2.1,3.7,4.2c0,3.1-2.4,4.9-6.3,4.9h-6.4V27.8h5.9c4.2,0,5.8,2.4,5.8,4.7c0,1.6-0.8,3.1-2.6,3.8V36.5 L166.8,36.5z M163.7,30.1h-3.5v5.3h3.6c1.9,0,2.9-0.9,2.9-2.7C166.7,30.7,165.3,30.1,163.7,30.1z M160.2,37.7v5.7h4.2 c1.9,0,3.4-0.9,3.4-2.8s-1.6-2.9-3.6-2.9L160.2,37.7L160.2,37.7z M179.1,45.6h-2.5V27.8h2.5V45.6z M199.9,40.7l0.3-0.1V27.8h2.5 v17.8l-1,0.3l-12.3-13l-0.3,0.1v12.7h-2.5V27.9l1-0.3L199.9,40.7z M220.1,41.5h-8.2l-1.9,4.3l-2.6-0.4l8.3-17.8h0.5l8.4,17.8 l-2.6,0.4L220.1,41.5z M212.9,39.2h6.1l-3-6.6h-0.1L212.9,39.2z M243.5,45v0.4l-2.4,0.5l-6.3-7.2h-2.9v7h-2.5V27.8h6.5 c3.7,0,6.1,2.2,6.1,5.3c0,2.7-1.6,4.7-4.4,5.2L243.5,45z M235.8,30.1h-3.8v6.3h3.8c2.3,0,3.7-1.1,3.7-3.3 C239.5,31.1,237.9,30.1,235.8,30.1z M248.5,41.7c1.5,1.2,3.2,1.9,5.6,1.9c3.1,0,4.2-1.3,4.2-2.7c0-1.6-1.5-2.3-4.5-3.6 c-4.1-1.8-5.5-2.9-5.5-5.2s2.1-4.7,6.1-4.7c2.7,0,4.9,0.9,6,1.9l-0.9,2.1c-1.5-1.1-3.2-1.6-5.1-1.6c-2.3,0-3.7,1-3.7,2.2 c0,1.3,1.1,1.9,4.7,3.4c4.1,1.6,5.4,3.3,5.4,5.7c0,3-2.6,4.9-6.9,4.9c-2.9,0-5.5-1.1-6.5-2.1L248.5,41.7z M122.8,4.6h-8.1v3h7.1v3.8 h-7.1v3.2h8.4v4H110V0.6h12.8L122.8,4.6L122.8,4.6z M141.2,10.9h0.2V0.6h4.7v18.1h-3l-9.7-10.3h-0.2v10.3h-4.7V0.6h3L141.2,10.9z M151.7,18.7V0.6h6.4c5.4,0,9.5,3.7,9.5,9.1c0,5.8-4,9.1-9.5,9.1C158.1,18.7,151.7,18.7,151.7,18.7z M158.4,14.7 c2.6,0,4.4-1.8,4.4-5.1c0-3.1-2.5-4.9-4.5-4.9h-2.1v10.1C156.2,14.7,158.4,14.7,158.4,14.7z M178.9,12.5H177v6.2h-4.7V0.6h6.7 c4.1,0,7,2.4,7,6.3C186,9.3,184.3,12.5,178.9,12.5z M178.5,4.4H177v4.5h1.6c1.5,0,2.5-0.7,2.5-2.1C181.1,5.5,180,4.4,178.5,4.4z M199.3,19.1c-5.7,0-9.7-4.1-9.7-9.3c0-5.8,4.7-9.5,9.7-9.5c4.9,0,9.7,3.7,9.7,9.5C208.9,14.9,205.1,19.1,199.3,19.1z M199.2,4.4 c-2.5,0-4.9,1.9-4.9,5.3c0,2.7,1.6,5.3,4.9,5.3c2.7,0,4.9-2,4.9-5.3C204.1,6.5,201.9,4.4,199.2,4.4z M218.6,18.7h-4.7V0.6h4.7V18.7z M237.3,10.9h0.2V0.6h4.7v18.1h-3l-9.7-10.3h-0.2v10.3h-4.7V0.6h3L237.3,10.9z M257,4.6v14.1h-4.7V4.6h-5.5v-4h15.6v4H257L257,4.6z M267.1,13.2c1.6,1,3.7,1.9,5.8,1.9c1.6,0,2.4-0.7,2.4-1.5c0-1.1-1.2-1.5-3.5-2.6c-3.7-1.7-5.2-3-5.2-5.7s2.2-5.2,6.7-5.2 c2.6,0,4.8,0.6,6.4,1.7l-1.2,3.8c-1.8-1-3.6-1.6-5.3-1.6c-1.4,0-2,0.5-2,1.3s0.7,1.2,3.6,2.5c3.9,1.8,5.3,3.5,5.3,5.9 c0,3.4-3.1,5.2-7.4,5.2c-3.1,0-5.8-1.1-6.9-2.1L267.1,13.2z"/> </svg> <button class="ui_form_close" data-dismiss="modal">close</button> </div> <div class="modal-body"> <div class="row"> <div class="col-12 modal-container"> <h1>Registration declined</h1> <h2>The future of cell therapy development and delivery</h2> <p class="mt-3">Apologies, the sponsor for this webinar has opted to block certain domains.</p> <p>Please feel free to check out our other upcoming webinars at <a href="https://webinars.endpts.com/">https://webinars.endpts.com/</a></p> </div> </div> </div> </div> </div> </div> <script src="https://webinars.endpts.com/assets/js/jquery-3.4.1.min.js" type="text/javascript"></script> <script src="https://webinars.endpts.com/assets/js/bootstrap.bundle.min.js" type="text/javascript"></script> <script src="https://webinars.endpts.com/assets/js/main.js?v=1.0.17" type="text/javascript"></script><script type='text/javascript'>/* <![CDATA[ */var webinar = {"id":84484013013,"title":"The future of cell therapy development and delivery","start":1692288000,"end":1692291600,"fields":{"email":{"name":"email","required":true},"first_name":{"name":"first_name","required":true},"last_name":{"name":"last_name","required":true},"country":{"name":"country","required":true,"answers":{"AF":"Afghanistan","AX":"\u00c5land Islands","AL":"Albania","DZ":"Algeria","AS":"American Samoa","AD":"Andorra","AO":"Angola","AI":"Anguilla","AQ":"Antarctica","AG":"Antigua and Barbuda","AR":"Argentina","AM":"Armenia","AW":"Aruba","AU":"Australia","AT":"Austria","AZ":"Azerbaijan","BS":"Bahamas","BH":"Bahrain","BD":"Bangladesh","BB":"Barbados","BY":"Belarus","BE":"Belgium","BZ":"Belize","BJ":"Benin","BM":"Bermuda","BT":"Bhutan","BO":"Bolivia","BQ":"Bonaire, Sint Eustatius and Saba","BA":"Bosnia and Herzegovina","BW":"Botswana","BV":"Bouvet Island","BR":"Brazil","IO":"British Indian Ocean Territory","BN":"Brunei Darussalam","BG":"Bulgaria","BF":"Burkina Faso","BI":"Burundi","CV":"Cabo Verde","KH":"Cambodia","CM":"Cameroon","CA":"Canada","KY":"Cayman Islands","CF":"Central African Republic","TD":"Chad","CL":"Chile","CN":"China","CX":"Christmas Island","CC":"Cocos (Keeling) Islands","CO":"Colombia","KM":"Comoros","CG":"Congo","CD":"Congo","CK":"Cook Islands","CR":"Costa Rica","CI":"C\u00f4te d'Ivoire","HR":"Croatia","CW":"Cura\u00e7ao","CY":"Cyprus","CZ":"Czechia","DK":"Denmark","DJ":"Djibouti","DM":"Dominica","DO":"Dominican Republic","EC":"Ecuador","EG":"Egypt","SV":"El Salvador","GQ":"Equatorial Guinea","ER":"Eritrea","EE":"Estonia","SZ":"Eswatini","ET":"Ethiopia","FK":"Falkland Islands (Malvinas)","FO":"Faroe Islands","FJ":"Fiji","FI":"Finland","FR":"France","GF":"French Guiana","PF":"French Polynesia","TF":"French Southern Territories","GA":"Gabon","GM":"Gambia","GE":"Georgia","DE":"Germany","GH":"Ghana","GI":"Gibraltar","GR":"Greece","GL":"Greenland","GD":"Grenada","GP":"Guadeloupe","GU":"Guam","GT":"Guatemala","GG":"Guernsey","GN":"Guinea","GW":"Guinea-Bissau","GY":"Guyana","HT":"Haiti","HM":"Heard Island and McDonald Islands","VA":"Holy See","HN":"Honduras","HK":"Hong Kong SAR","HU":"Hungary","IS":"Iceland","IN":"India","ID":"Indonesia","IQ":"Iraq","IE":"Ireland","IM":"Isle of Man","IL":"Israel","IT":"Italy","JM":"Jamaica","JP":"Japan","JE":"Jersey","JO":"Jordan","KZ":"Kazakhstan","KE":"Kenya","KI":"Kiribati","KR":"Korea","KW":"Kuwait","KG":"Kyrgyzstan","LA":"Lao People's Democratic Republic","LV":"Latvia","LB":"Lebanon","LS":"Lesotho","LR":"Liberia","LY":"Libya","LI":"Liechtenstein","LT":"Lithuania","LU":"Luxembourg","MO":"Macau SAR","MG":"Madagascar","MW":"Malawi","MY":"Malaysia","MV":"Maldives","ML":"Mali","MT":"Malta","MH":"Marshall Islands","MQ":"Martinique","MR":"Mauritania","MU":"Mauritius","YT":"Mayotte","MX":"Mexico","FM":"Micronesia","MD":"Moldova","MC":"Monaco","MN":"Mongolia","ME":"Montenegro","MS":"Montserrat","MA":"Morocco","MZ":"Mozambique","MM":"Myanmar","NA":"Namibia","NR":"Nauru","NP":"Nepal","NL":"Netherlands","NC":"New Caledonia","NZ":"New Zealand","NI":"Nicaragua","NE":"Niger","NG":"Nigeria","NU":"Niue","NF":"Norfolk Island","MP":"Northern Mariana Islands","MK":"North Macedonia","NO":"Norway","OM":"Oman","PK":"Pakistan","PW":"Palau","PS":"Palestine","PA":"Panama","PG":"Papua New Guinea","PY":"Paraguay","PE":"Peru","PH":"Philippines","PN":"Pitcairn","PL":"Poland","PT":"Portugal","PR":"Puerto Rico","QA":"Qatar","RE":"R\u00e9union","RO":"Romania","RU":"Russian Federation","RW":"Rwanda","BL":"Saint Barth\u00e9lemy","SH":"Saint Helena, Ascension and Tristan da Cunha","KN":"Saint Kitts and Nevis","LC":"Saint Lucia","MF":"Saint Martin (French part)","PM":"Saint Pierre and Miquelon","VC":"Saint Vincent and the Grenadines","WS":"Samoa","SM":"San Marino","ST":"Sao Tome and Principe","SA":"Saudi Arabia","SN":"Senegal","RS":"Serbia","SC":"Seychelles","SL":"Sierra Leone","SG":"Singapore","SX":"Sint Maarten (Dutch part)","SK":"Slovakia","SI":"Slovenia","SB":"Solomon Islands","SO":"Somalia","ZA":"South Africa","GS":"South Georgia and the South Sandwich Islands","SS":"South Sudan","ES":"Spain","LK":"Sri Lanka","SR":"Suriname","SJ":"Svalbard and Jan Mayen","SE":"Sweden","CH":"Switzerland","TW":"Taiwan","TJ":"Tajikistan","TZ":"Tanzania","TH":"Thailand","TL":"Timor-Leste","TG":"Togo","TK":"Tokelau","TO":"Tonga","TT":"Trinidad and Tobago","TN":"Tunisia","TR":"Turkey","TM":"Turkmenistan","TC":"Turks and Caicos Islands","TV":"Tuvalu","UG":"Uganda","UA":"Ukraine","AE":"United Arab Emirates","GB":"United Kingdom","UM":"United States Minor Outlying Islands","US":"United States of America","UY":"Uruguay","UZ":"Uzbekistan","VU":"Vanuatu","VE":"Venezuela","VN":"Viet Nam","VG":"Virgin Islands (British)","VI":"Virgin Islands (U.S.)","WF":"Wallis and Futuna","EH":"Western Sahara","YE":"Yemen","ZM":"Zambia","ZW":"Zimbabwe","Other":"Other"}},"org":{"name":"org","required":true},"job_title":{"name":"job_title","required":true}},"vimeo_link":"https:\/\/vimeo.com\/855465930\/e495f4bfdc"};/* ]]> */</script><script>!function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}; if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0'; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)}(window, document,'script', 'https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '174990157837477'); fbq('track', 'PageView'); _linkedin_partner_id = "2273916"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); (function(){var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);})(); (function(w,d,t,r,u){var f,n,i;w[u]=w[u]||[],f=function(){var o={ti:"56366962"};o.q=w[u],w[u]=new UET(o),w[u].push("pageLoad")},n=d.createElement(t),n.src=r,n.async=1,n.onload=n.onreadystatechange=function(){var s=this.readyState;s&&s!=="loaded"&&s!=="complete"||(f(),n.onload=n.onreadystatechange=null)},i=d.getElementsByTagName(t)[0],i.parentNode.insertBefore(n,i)})(window,document,"script","//bat.bing.com/bat.js","uetq"); </script> </body> </html>

Pages: 1 2 3 4 5 6 7 8 9 10